Publications by authors named "Keith Karcher"

Claim this Profile
S
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
Carlo Antozzi, Tuan Vu, Sindhu Ramchandren, Richard J Nowak, Constantine Farmakidis, Keith Karcher

Lancet Neurol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies.
Randall L Morrison, Jaskaran Singh, Ella Daly, Maggie Fedgchin, Rachel Ochs-Ross, Keith Karcher

Int J Neuropsychopharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study.
Carlo Antozzi, Jeffrey Guptill, Vera Bril, Josep Gamez, Sven G Meuth, Keith Karcher

Neurology· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial.
Reisa Sperling, David Henley, Paul S Aisen, Rema Raman, Michael C Donohue, Keith Karcher

JAMA Neurol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients.
Robert Howard, Sergi G Costafreda, Keith Karcher, Danielle Coppola, Jesse A Berlin

Br J Psychiatry· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapentadol immediate-release for acute postbunionectomy pain: a phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan.
Yeung-Jen Chen, Chao-Ching Chiang, Peng-Ju Huang, Jason Huang, Keith Karcher

Curr Med Res Opin· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
Hans G Kress, E Dietlind Koch, Hristiyan Kosturski, Achim Steup, Keith Karcher

Pain Physician· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy.
Aaron I Vinik, Douglas Y Shapiro, Christine Rauschkolb, Bernd Lange, Keith Karcher

Diabetes Care· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder.
Justine M Kent, David Hough, Jaskaran Singh, Keith Karcher, Gahan Pandina

J Child Adolesc Psychopharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study.
Justine M Kent, Stuart Kushner, Xiaoping Ning, Keith Karcher, Seth Ness

J Autism Dev Disord· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials.
Srihari Gopal, David Hough, Keith Karcher, Isaac Nuamah, Joseph Palumbo

J Clin Psychopharmacol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia.
Gahan Pandina, Stuart Kushner, Keith Karcher, Magali Haas

Child Adolesc Psychiatry Ment Health· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases.
Larry Alphs, Srihari Gopal, Keith Karcher, Justine Kent, Jennifer Kern Sliwa

Curr Drug Saf· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder.
Jorge A Quiroz, Lakshmi N Yatham, Joseph M Palumbo, Keith Karcher, Stuart Kushner

Biol Psychiatry· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.
Magali Haas, Keith Karcher, Gahan J Pandina

J Child Adolesc Psychopharmacol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.
Nicholas A Keks, Michael Ingham, Akbar Khan, Keith Karcher

Br J Psychiatry· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.
Robert M A Hirschfeld, Mariëlle Eerdekens, Amir H Kalali, Carla M Canuso, Akbar A Khan, Keith Karcher

Int Clin Psychopharmacol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.
Anatoly B Smulevich, Sumant Khanna, Mariëlle Eerdekens, Keith Karcher, Michelle Kramer

Eur Neuropsychopharmacol· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.
Robert M A Hirschfeld, Paul E Keck, Michelle Kramer, Keith Karcher, Carla Canuso

Am J Psychiatry· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
W Wolfgang Fleischhacker, Mariëlle Eerdekens, Keith Karcher, Gary Remington, Pierre-Michel Llorca

J Clin Psychiatry· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
John M Kane, Mariëlle Eerdekens, Jean-Pierre Lindenmayer, Samuel J Keith, Michael Lesem, Keith Karcher

Am J Psychiatry· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis